MoonLake Immunotherapeutics (MLTX)
NasdaqCM · USD · Healthcare · Biotechnology
$11.81 (-0.34%) as of
Key statistics
- Market cap
- 1.01B
- Forward P/E
- -3.55
- EPS (TTM)
- -3.83
- Dividend yield
- 0.00%
- 52-week range
- 9.37 – 23.29
- Beta
- 1.08
- Profit margin
- 0.00%
- Analyst target
- $28.54
- Volume
- 1.51M
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Zug, Switzerland
- Employees
- 130
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.